---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-045673"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:40:43.889539+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026

## Summary
- Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.
- Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.
- Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.
- Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025.

## SEC filing metadata
- accession: 0001193125-25-045673
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/0001193125-25-045673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312525045673/d924521d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-045673
- JSON: https://secwatch.observer/filing/0001193125-25-045673.json
- Plain text: https://secwatch.observer/filing/0001193125-25-045673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.